Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Brian Lindman Added: 3 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in… View more
Author(s): Diana Hui Ping Foo Added: 1 month ago
ESC HF 25 - Findings from Heart2Miss suggest a hub-and-spoke model for early heart failure detection can detect patients with pre-HF and HF who were previously undiagnosed, can reduce tertiary center overload and improve novice performance.Dr Diana Foo (Sarawak General Hospital, Kuching, MY) discusses the findings from the Heart2Miss study, investigating a decentralised, community-based, rapid,… View more
Author(s): Christophe Leclercq Added: 3 months ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire… View more
Author(s): David Ferreira Added: 10 months ago
ESC Congress 24 — Fasting prior to cardiac catheterisation surgery significantly improves patient satisfaction score.We are joined onsite by Dr David Ferreira (John Hunter Hospital, AU) to discuss the findings from the SCOFF Trial (ACTRN12622001455752), which randomized 716 patients in a 1:1 fashion to either a no fasting group, or a fasting group. The fasting group were allowed solid foods 6… View more
Author(s): David Austin Added: 1 year ago
ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574).Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicity.PROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced… View more